You have access
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
ANA LAURA ORTEGA-GRANADOS, ÁNGEL ARTAL-CORTES, DAVID AGUIAR-BUJANDA, JUANA ORAMAS, JOSÉ LUIS FÍRVIDA, JAVIER DE CASTRO, JUANA CAMPILLO FUENTES, ROCÍO GORDO, RAQUEL GALÁN, JOSÉ TRIGO and on behalf of the ASPET Study Investigators
Anticancer Research March 2019, 39 (3) 1317-1328; DOI: https://doi.org/10.21873/anticanres.13244